The global cancer stem cell market revenue was valued at US$ 1.5 billion in 2021 and is projected to reach US$ 2.9 billion by 2031. The market will register a CAGR (Compound Annual Growth Rate) of 10% during the forecast period from 2022 to 2031.

Cancer stem cells are exceptional because they can separate into many lineages and multiply in large numbers. These cells are present in the majority of organs, such as the prostate, lungs, brain, and other tissues Cancer stem cells provide significant benefits for cancer therapy.

Factors Influencing Market Growth

Growth in R&D activities that support the creation of drugs to cure cancer, which is leading the death cause. Thus, this factor fuels the market growth.

Due to the increasing incidence of cancer in the world, there is a greater demand for a safe and effective treatment that would eradicate cancer cells in the body while lowering the patient's chance of metastasis or relapse. Such a factor drives market expansion.

Research studies and financing for new cancer treatments are both rising quickly. Thus, it is anticipated to propel the market growth.

The high expense of stem cell therapy therapies and the stringent healthcare agency restrictions constrain market growth.


COVID-19 Pandemic Effect on Market Growth

The COVID-19 pandemic had a positive impact on the market. The advent of genetic engineering, which modifies human DNA, and organoid technology, which creates the three-dimensional structure of the tissue from originating stem cells, are two of the most significant strides in stem cell research during the pandemic.

Regional Analysis

Asia Pacific region is anticipated to have consistent revenue growth over the forecast period. Due to the constant expansion of healthcare facilities, supportive government-funded programs on cancer research, a sizable patient population, and the rising prevalence of chronic diseases. China, Japan, and India are the top three revenue-generating countries in the region for the cancer stem cell market
Leading Competitors
The leading companies in the global cancer stem cells market are:
Thermo Fisher Scientific Inc.
AbbVie Inc.
Miltenyi Biotec
STEMCELL Technologies Inc
Merck KGaA
Stemline Therapeutics, Inc.
MacroGenics, Inc.
Bionomics
FUJIFILM Irvine Scientific.
Lineage Cell Therapeutics, Inc.
Others
Segmentation Analysis
The global cancer stems cell market segmentation focuses on Cancer Forms, Applications, and Regions.
Segmentation Based on Cancer Forms
Breast
Blood
Lung
Brain
Colorectal
Pancreatic
Bladder
Liver
Others
Segmentation Based on Applications
Targeted Cancerous Stem Cells
Stem Cell-based Cancer Therapy
Segmentation Based on Region
North America
U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Europe

Asia-Pacific
China
India
Japan, South Korea
ASEAN
Rest of Asia-Pacific

Middle East & Africa (MEA)
Brazil
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America